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A B S T R A C T
We investigated whether the relation between liver fat and subclinical atherosclerosis is mediated by
low-grade systemic inﬂammation in type 2 diabetes (T2DM) and the metabolic syndrome (MetS).
In 16 T2DM, 36 MetS, and 21 age-matched healthy men, liver fat was quantiﬁed by 1H-MRS. Carotid
intima–media thickness (cIMT) was measured by ultrasound. Differences between controls, MetS and
T2DM or between high versus low liver fat content were calculated. Furthermore, the association of liver
fat content, cIMT and CRP was assessed.
Liver fat percentage was highest in T2DM, as compared to MetS and controls [17.5% (8.0–27.6), 8.2%
(4.2–14.2) and 5.3% (2.3–7.4), respectively; P < 0.001]. Subjects with high-liver fat content had increased
cIMT and CRP (all P < 0.02). Liver fat content was positively associated with cIMT (r = 0.37; P = 0.003).
The association of liver fat content and cIMT disappeared after adjustment for CRP.
The association between liver fat content and subclinical atherosclerosis seems mediated by low-
grade inﬂammation, possibly due to increased hepatic production. Lowering of liver fat content may
decrease CVD risk by concomitantly reducing the pro-inﬂammatory state in high-risk populations.
 2010 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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The incidence of non-alcoholic fatty liver disease (NAFLD)
increases globally and, consequently, has gained increasing interest
in recent years [1]. NAFLD is characterized by triglyceride
accumulation in hepatocytes and includes a wide spectrum of liver
pathology, ranging from benign liver steatosis to non-alcoholic
steatohepatitis (NASH), the latter which may progress to cirrhosis
[1]. NAFLD develops without a history of excessive alcohol
consumption or positive tests for viral and auto-immune liver
diseases [1,2]. NAFLD is highly prevalent in insulin resistant subjects§ Grant support: This research received no speciﬁc grant from any funding agency
in the public, commercial, or not-for-proﬁt sectors.
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1871-4021/$ – see front matter  2010 Diabetes India. Published by Elsevier Ltd. All r
doi:10.1016/j.dsx.2010.05.018such as individuals with the MetS and T2DM [3–6], who are
additionally characterized by an increased cardiovascular disease
(CVD) risk [7]. Indeed, several studies have demonstrated that
NAFLD is associatedwith CVD [8], carotid artery atherosclerosis [9–
11] and endothelial dysfunction [12], independent of classical risk
factors such as insulin resistance and components of the MetS.
Although the mechanisms underlying the association of NAFLD
and CVD still remain to be clariﬁed, NAFLD is characterized by an
increased pro-inﬂammatory state, including elevated plasma C-
reactive protein (CRP) levels [3,13]. CRP is marked as an
independent predictor of future CVD events [14–16]. Therefore,
this pro-inﬂammatory phenotype may underlie the association
between liver fat and CVD risk. Carotid intima–media thickness
(cIMT), assessed by ultrasound, is a validated parameter for
subclinical atherosclerosis [17], predictive of both myocardial
infarction and stroke [18]. cIMT has been related to the severity of
liver damage in NAFLD, as measured by liver biopsy [19] and by
ultrasound [11]. However, at present, the inter-relationship of liver
fat accumulation, subclinical atherosclerosis and a pro-inﬂamma-
tory state is still incompletely understood.ights reserved.
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and subclinical atherosclerosis may be mediated by low-grade
systemic inﬂammation, reﬂected by increased CRP concentrations.
To this purpose, we measured liver fat by proton magnetic
resonance spectroscopy (1H-MRS) [20], cIMT by ultrasound and
plasma CRP concentrations in men with uncomplicated T2DM, the
MetS and healthy age-matched controls.
2. Materials and methods
2.1. Study population
After written informed consent, 73 Caucasian males, aged 40–
65 years, with known T2DM (n = 16), MetS (n = 36) and healthy
controls (n = 21) were studied. Diet, sulphonylurea and/or
metformin were the only blood glucose-lowering treatments
allowed in the T2DM group. Subjects with theMetS or T2DMwere
allowed to use low dose blood pressure lowering medication
(angiotensin receptor antagonists, angiotensin converting en-
zyme inhibitors, calcium channel blockers or thiazide diuretics).
Exclusion criteria comprised claustrophobia, smoking, excessive
alcohol intake (>20 units/week), history of hepatitis and/or
pancreatitis, history of CVD, abnormal liver and renal function
tests (>2 times upper limits of normal), recent (<3 months)
changes inmedication or weight (5%) and any othermedication.
The study was approved by the local Ethics Committee and
was performed in line with the Helsinki Declaration of human
rights.
2.2. Study protocol
Following an overnight fast, the subjects arrived at the hospital
clinical research unit in themorning for ultrasound examination of
the common carotid artery and venous blood sampling. At a
separate visit, liver fat content was measured in the fasting state
using 1H-MRS. All measurements were completed within 4 weeks
after the screening visit.
2.3. Laboratory analysis
Baseline plasma glucose concentrations were determined by
the hexokinase-method (Gluco-quant, Roche Diagnostics, Man-
nheim, Germany). Haemoglobin A1c (HbA1c) was measured with
cation exchange chromatography (Menarini Diagnostics, Florence,
Italy). The local reference range for nondiabetic subjects is 4.3–
6.1%. Total cholesterol, high-density lipoprotein cholesterol (HDL-
C) and triglycerides (TG) were determined by enzymatic methods
(Modular, Hitachi, Japan). Low-density lipoprotein cholesterol
(LDL-C) was calculated with the Friedewald formula [21]. Insulin
(reference cut-off value: <20 mU/mL) was determined by radio-
immunoassay (Medgenix, Brussels, Belgium). Insulin resistance
was evaluated by using the index HOMA-IR (homeostasis model
assessment of insulin resistance) [HOMA-IR: fasting plasma
glucose (mmol/L)  fasting serum insulin (mU/mL)/22.5] [22].
CRP was determined by a highly sensitive, latex particle-enhanced
immunoturbidimetric assay (reference range: 0.1–6.0 mg/L; intra-
assay coefﬁcient of variation (CV) was 4% and inter-assay CV was
6%).
2.4. Diagnosis of the metabolic syndrome
The MetS was diagnosed according to criteria of the Interna-
tional Diabetes Federation (IDF) [23]. To this end, central obesity
(waist circumference 90 cm in men) and two or more of the
following criteria should be present: (1) hypertriglyceridaemia
(1.7 mmol/L), or speciﬁc treatment for this lipid abnormality; (2)low HDL-C (<0.9 mmol/L in men), or speciﬁc treatment for this
lipid abnormality; (3) high blood pressure (130/85 mm Hg), or
treatment of previously diagnosed hypertension; (4) hypergly-
caemia: fasting plasma glucose level 5.6 mmol/L, and/or 2-h
postload plasma glucose level 7.8 mmol/L. T2DM patients were
not included in the MetS group.
2.5. Assessment of common cIMT
Ultrasonography scanning of the right common carotid artery
was performed in order to measure cIMT. Measurements were
performed by an experienced investigator employing a B-mode
ultrasound imager with a 7.5 MHz linear-array transducer (Esaote,
Maastricht, The Netherlands). Examination took place in the
supine position, with the subjects’ head turned slightly to the
contralateral (left) side. When optimal longitudinal images were
captured during the systole of a single heartbeat, they were stored
for off-line analysis using the Wall Track System 2 software
(Neurodata, Bilthoven, The Netherlands). Subsequently, the
thickness of the intima–media complex (i.e. the distance between
the edge of the ﬁrst and second echogenic lines) was measured on
the posterior (far) wall of the common carotid artery at about
10 mm proximal to the carotid bulb. For each subject, ultrasound
data were obtained during three consecutive measurements, each
comprising a 4-s period (approximately 4 heart beats). The mean
cIMT was used in the analyses. A study of the intra-observer
reproducibility of cIMT measurements in 10 healthy subjects
revealed a CV of less than 2%.
2.6. Quantiﬁcation of liver fat content
Quantiﬁcation of liver fat content was performed by 1H-MRS
with the subject in the supine position using a 1.5-T whole-body
magnetic resonance scanner (Sonata; Siemens, Erlangen, Ger-
many), as previously described [20,24]. For the localization of the
voxel of interest (VOI) both axial and coronal high resolution
magnetic resonance imaging scans were used. A 8–15 cm3 VOI
(voxel length ranging from 2.0 to 2.5 cm) was placed at three
positions in the liver (right anterior, right posterior, andmedial or
left anterior) avoiding vascular structures, intrahepatic bile ducts,
subcutaneous fat tissue and the lateral margin of the liver.
Spectral quantiﬁcation was performed with LC Model (version
6.1) [25]. Triglyceride content was expressed as the ratio of the
area under the methyl (0.9 ppm) and methylene peaks (1.3 ppm)
relative to the area under the water peak (4.65 ppm) [19]. The
ﬁnally used triglyceride content was the mean of three VOIs. All
measurements were analyzed by analysts unaware of the
subjects’ clinical data. High-liver fat content was deﬁned as
having a liver fat content 5.56%, whereas subjects with liver fat
content <5.56% were designated as having low liver fat content
[20]. The CV between two repeated assessments of liver fat
content was 4.7% [24].
2.7. Statistical analyses
Results are presented as mean values  standard deviation (SD)
or, in case of skewed distribution, as median values (interquartile
range; IQR). Non-Gaussian distributed data, based on QQ-plots, were
log-transformed to normality before analysis. Between-group differ-
ences, i.e. between controls, MetS and T2DM or between high versus
low liver fat content, were calculated by analysis of variance (ANOVA)
and Bonferroni post hoc analysis was used to correct for multiple
comparisons. The associations between cIMT and selected cardio-
metabolic risk factors were assessed by univariate correlations. The
role of CRP as a mediator in the associations between liver fat content
and cIMT was assessed by multivariate regression analysis. In this
Table 2
Biochemical and clinical differences in subjects with low- versus high-liver fat
content.
Liver fat
content
<5.56% (n=26)
Liver fat
content
5.56% (n=47)
P-Value
Age (years) 557.9 576.0 0.43
Body mass index (kg/m2) 272.4 313.4 <0.001
Waist circumference (cm) 100.57 1108.8 <0.001
Fasting plasma
glucose (mmol/L)
5.6 (5.4–6.1) 6.1 (5.5–7.5) 0.027
HbA1c (%) 5.6 (5.5–6.1) 6.0 (5.7–6.5) 0.005
Plasma glucose
2-h (mmol/L)
5.7 (5.1–6.4) 7.3 (6.1–10.6 0.001
ALT (U/L) 22 (17–28) 33 (26–45) <0.001
Total cholesterol (mmol/L) 5.2 0.8 5.2 0.9 0.94
HDL-C (mmol/L) 1.4 0.4 1.1 0.2 0.001
LDL-C (mmol/L) 3.1 0.6 3.2 0.8 0.59
Triglycerides (mmol/L) 1.1 (0.9–1.5) 1.6 (1.1–2.3) 0.007
Fasting insulin (pmol/L) 32 (24–49) 67 (47–85) <0.001
HOMA-IR 1.2 (0.8–2.0) 2.6 (1.9–3.5) <0.001
cIMT (mm) 0.65 0.2 0.74 0.1 0.016
CRP (mg/L) 0.9 (0.4–1.8) 1.7 (0.9–2.9) 0.001
Values aremeans (standard deviation) ormedians (interquartile range). ALT, alanine
aminotransferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resis-
tance; cIMT, carotid intima–media thickness; CRP, C-reactive protein.
Table 1
Clinical characteristics in males with T2DM, the MetS and healthy controls.
Controls (n=21) MetS (n=36) T2DM (n=16) P-Value
Age (years) 55.97.9 56.66.9 55.44.8 0.84
Body mass index (kg/m2) 27.73.2 29.4 2.8 31.74.2z 0.001
Waist circumference (cm) 101.69.0 107.58.2* 110.89.7* 0.006
Systolic blood pressure (mmHg) 12611 13614* 13513 0.021
Diastolic blood pressure (mmHg) 787 867z 825 <0.001
Fasting plasma glucose (mmol/L) 5.4 (5.1–5.5) 6.0 (5.6–6.3)* 8.1 (7.5–9.9)z,§ <0.001
HbA1c (%) 5.5 (5.4–5.8) 5.9 (5.6–6.1) 6.9 (6.5–8.0)z,§ <0.001
Plasma glucose 2-h (mmol/L) 5.5 (4.5–6.5) 6.6 (5.9–8.0)* 14.9 (12.4–17.1)z,§ <0.001
Fasting insulin (pmol/L) 34.7 (23.1–62.6) 55.5 (43.1–81.8)z 77.2 (42.2–82.2)z <0.001
HOMA-IR 1.2 (0.8–2.0) 2.2 (1.6–3.4)z 3.1 (2.2–5.6)z,y <0.001
Total cholesterol (mmol/L) 5.20.8 5.21.0 5.0 0.6 0.77
HDL-C (mmol/L) 1.50.4 1.1 0.3z 1.1 0.3z <0.001
LDL-C (mmol/L) 3.20.7 3.3 0.8 3.1 0.6 0.72
Triglycerides (mmol/L) 1.0 (0.8–1.1) 1.7 (1.2–2.3)z 1.8 (1.3–2.8)z <0.001
Gamma-GT (U/L) 21 (16–30) 33 (23–42)* 33 (27–42)* 0.001
ALT (U/L) 23 (17–40) 30 (22–44) 31 (25–48) 0.073
Medication
Blood pressure lowering (%) 0 18 15 0.17
Oral blood glucose lowering (%) 0 0 62 <0.001
Values are means (standard deviation) or medians (interquartile range). T2DM, type 2 diabetes; MetS, metabolic syndrome; ALT, alanine aminotransferase; HDL-C, HDL-
cholesterol; LDL-C, LDL-cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance.
* P<0.05 compared to CO.
z P<0.001 compared to CO.
y P<0.05 T2DM compared to MetS.
§ P<0.001 T2DM compared to MetS.
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controls, MetS and T2DM) on the relationship between liver fat
content and cIMT was evaluated by adding a composite interaction
term. A P-value of <0.05 was considered statistically signiﬁcant. For
interaction-terms, a P-value of <0.1 was considered statistically
signiﬁcant. All statistical analyses were performed with SPSS version
15.0 (SPSS, Chicago, IL, USA).
3. Results
The baseline clinical and biochemical characteristics of the
subjects are listed in Table 1. As expected, T2DM patients had the
highest BMI, waist circumference, heart rate, HbA1c, fasting
plasma glucose, 2-h plasma glucose, triglyceride concentrations,
fasting plasma insulin concentrations, and HOMA-IR, whereas
their HDL-C concentrations were lowest. Males with the MetS had
the highest blood pressure levels.
Liver fat content gradually increased over the three groups
from 5.3% (2.3–7.4) (median (IQR)), 8.2% (4.2–14.2) and 17.5%
(8.0–27.6), P < 0.001 for controls, MetS, and T2DM, respectively.
Mean (SD) cIMT was increased in MetS and T2DM compared to
controls (controls: 0.64 mm  0.14, MetS: 0.71 mm  0.16 and
T2DM: 0.69 mm  0.12, P = 0.035). CRP levels were highest in
T2DM subjects (T2DM: 1.9 mg/L (0.9–3.0), MetS: 1.2 mg/L (0.9–
2.6) and controls: 0.9 mg/L (0.4–2.0), P = 0.034). Of T2DM, 87% had
high-liver fat content, as compared to 69% of MetS and 38% of
controls (P = 0.005). When subjects were divided according to high
versus low liver fat content, those with high-liver fat content had
more CVD associated risk factors, including increased CRP and cIMT
(Table 2).
3.1. Associations of liver fat content, CRP and cIMT
Positive correlations were found between liver fat content and
cIMT (r = 0.28; P = 0.03; Fig. 1A) and liver fat content and CRP
(r = 0.29; P = 0.03; Fig. 1B). In univariate analyses only age, systolic-
and diastolic blood pressure correlated signiﬁcantly (r = 0.35,
P = 0.005; r = 0.26, P = 0.037; r = 0.26, P = 0.041, respectively) with
cIMT (Table 2).To further analyse the independent relationship of liver fat
content and subclinical atherosclerosis we used multivariate
regression analyses (Table 3). Since the association between liver
fat content and subclinical atherosclerosis did not differ in the
three groups separately (P-value of interaction term >0.1), effect
modiﬁcation was excluded and pooled analyses were performed.
Model 1 describes the relation between liver fat content and cIMT.
Glucometabolic state was added to themodel to adjust for possible
confounding (Model 2). When CRP was added to the model, the
association between liver fat and cIMT was attenuated and lost
signiﬁcance, while a strong association between cIMT and CRP
remained (Model 3). After adjustment for age and blood pressure
the relation between CRP and cIMT sustained (Model 4).
Table 3
Multivariate associations between liver fat content and cIMT.
DcIMT (mm) (95% CI) Pa r r2 Pb
Model 1 0.25 0.064 0.039
Liver fat content (%) 0.09 (0.04–0.17) 0.04
Model 2 (Model 1+glucometabolic state) 0.25 0.064 0.089
Liver fat content (%) 0.09 (0.004–0.18) 0.05
Glucometabolic state 0.05 (0.06 to 0.05) 0.86
Model 3 (Model 2+CRP) 0.34 0.11 0.029
Liver fat content (%) 0.04 (0.06 to 0.13) 0.44
Glucometabolic state 0.009 (0.057 to 0.074) 0.79
CRP (mg/L) 0.12 (0.006 to 0.24) 0.06
Model 4 (Model 3+ age and BP) 0.57 0.32 <0.001
Liver fat content (%) 0.001 (0.09 to 0.09) 0.97
Glucometabolic state 0.014 (0.075 to 0.047) 0.64
CRP (mg/L) 0.13 (0.03–0.24) 0.04
Age (years) 0.009 (0.004–0.015) 0.015
Systolic BP (mmHg) 0.001 (0.002 to 0.005) 0.005
Diastolic BP (mmHg) 0.004 (0.003 to 0.01) 0.011
Multivariable linear regression analyses; in Models 1–4, cIMT was the dependent variable. Independent variables were: log liver fat content (Model 1); log liver fat content
and glucometabolic state (i.e. controls, MetS or T2DM) (Model 2); log liver fat content and log CRP (Model 3). Models 1–3 are uncorrected for other cardiovascular risk factors
or components of the metabolic syndrome. In Model 4, Model 3 is corrected for age, systolic blood pressure and diastolic blood pressure. cIMT, carotid artery intima–media
thickness; CI, conﬁdence interval; CRP, C-reactive protein; BMI, body mass index; BP, blood pressure.
a Level of signiﬁcance for the association between cIMT and the separate components of the model.
b Level of signiﬁcance of the model.
Fig. 1. Scatterplots showing the relationship of liver fat content and carotid artery
intima–media thickness (cIMT) (A) and liver fat content and plasma C-reactive
protein (CRP) concentrations (B) in males with type 2 diabetes (asterisk), the MetS
(dot) and healthy controls (triangle).
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The present study demonstrates that subjects with high versus
low liver fat content had higher CRP concentrations and more
marked subclinical atherosclerosis, represented by an increased
cIMT, irrespective of their glucometabolic differences. Further-
more, the positive association between liver fat content and carotid
artery subclinical atherosclerosis disappeared after adjustment forplasma CRP concentration, suggesting that this circulating pro-
inﬂammatory marker, that is largely derived from the liver,
mediates the relation between the fatty liver and subclinical
atherosclerosis in T2DM patients, subjects with the MetS and
healthy controls.
The relation between NAFLD and markers of CVD is well
established [9–12,19]. However, the mechanisms by which
increased liver fat content could accelerate atherogenesis are
not conclusive. The association between NAFLD and atherosclero-
sis may reﬂect the overall atherogenic condition pertinent to
insulin resistant states such as the MetS and T2DM [1,7]. Insulin
resistance results in decreased inhibition of hepatic glucose
production, increased hepatic output of TG-rich lipoproteins but
also decreased glucose utilization and lipolysis [3], leading to
hyperglycaemia [26], hypertriglyceridaemia and increased circu-
lating non-esteriﬁed fatty acids (NEFA) [27]. The increased lipid
availability in the liver provides an atherogenic dyslipidaemic
milieu with increased rates of hepatic triglyceride synthesis and
VLDL particle production resulting in low HDL-cholesterol and
increased small dense LDL particles [26–28]. In our study,
differences in lipid proﬁle could not explain the increase in
subclinical atherosclerosis in subjects with high-liver fat content
as compared tot subjects with low liver fat content.
Increased ﬂuxes of NEFA, in addition to dietary chylomicrons
and de novo intrahepatic lipogenesis, the latter driven by abundant
substrate supply in the presence of hyperglycaemia, will result in
intrahepatic triglyceride and lipid accumulation [1–3]. Besides,
when NEFA exceeds oxidative capacity, this will lead to the
formation of toxic intermediates, and ultimately to mitochondrial
dysfunction and increased oxidative stress in NAFLD, which in turn
results in cell damage and increased release of inﬂammatory
cytokines, e.g. CRP [29]. Additionally, increased production of
adipocytokines, including tumor necrosis factor-alpha and inter-
leukin-6, by adipose tissue enhances the production of pro-
inﬂammatory cytokines in the fatty liver. The ensuing systemic
inﬂammation may play a key role in the increased CVD risk in
subjects with NAFLD [29–31]. In our study liver fat content,
gradually increased with deterioration of glucometabolic vari-
ables, regarded as MetS and T2DM, and this was paralleled by
elevation of CRP. Furthermore, multivariate analyses outlined the
role of CRP in the relationship between liver fat content and
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derived from our cross-sectional data, we may hypothesize that
the increased CRP levels, possibly due to increased hepatic
production, can directly or indirectly mediate the relationship
between NAFLD and CVD.
Certain limitations of our study should be acknowledged, such
as the cross-sectional design that precludes conclusions regarding
causality of the found associations. Secondly, the use of HOMA-IR
instead of an euglycaemic–hyperinsulinaemic clamp to estimate
insulin resistance. HOMA-IR may be less reliable in subjects with
fatty liver, since liver fat impairs insulin clearance [32], and in
subjects with T2DM, where elevated fasting plasma glucose may
drive the HOMA-IR value. Finally, although an excellent correlation
exists between 1H-MRS-measured liver fat content and the fat
content quantiﬁed in liver biopsy specimen [20], the gold-standard
biopsy technique may provide additional information regarding
the presence of an inﬂammatory component or the severity of
NASH.
In conclusion, we have demonstrated that liver fat content is
associated with subclinical atherosclerosis, and that this associa-
tion may be mediated by CRP, a pro-inﬂammatory marker that is
known to be largely derived from the liver. A clinical diagnosis of
NAFLD or an expected high-liver fat content, as concurs often with
theMetS/T2DMphenotype, should prompt clinicians to evenmore
aggressively treat the associated CVD risk factors to lower CVD risk.
References
[1] Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221–
31.
[2] Brunt EM. Nonalcoholic steatohepatitis: deﬁnition and pathology. Semin Liver
Dis 2001;21(1):3–16.
[3] Kotronen A, Yki-Ja¨rvinen H. Fatty liver: a novel component of the metabolic
syndrome. Arterioscler Thromb Vasc Biol 2008;28(1):27–38.
[4] Schindhelm RK, Diamant M, Heine RJ. Nonalcoholic fatty liver disease and
cardiovascular disease risk. Curr Diab Rep 2007;7(3):181–7.
[5] Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-
alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr
1999;18(6):353–8.
[6] Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al.
Nonalcoholic fatty liver disease: a feature of themetabolic syndrome. Diabetes
2001;50(8):1844–50.
[7] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;
365(9468):1415–28.
[8] Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic
fatty liver disease and risk of future cardiovascular events among type 2
diabetic patients. Diabetes 2005;54(12):3541–6.
[9] Brea A, Mosquera D, Martı´n E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty
liver disease is associated with carotid atherosclerosis: a case–control study.
Arterioscler Thromb Vasc Biol 2005;25(5):1045–50.
[10] Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al.
Carotid artery intima–media thickness in nonalcoholic fatty liver disease. Am J
Med 2008;121(1):72–8.
[11] Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, et al. Non-alcoholic
fatty liver disease is associated with carotid artery wall thickness in diet-
controlled type 2 diabetic patients. J Endocrinol Invest 2006;29(1):55–60.[12] Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T,
et al. Liver alanine aminotransferase, insulin resistance and endothelial dys-
function in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur
J Clin Invest 2005;35(6):369–74.
[13] Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH
predicts plasma inﬂammatory biomarkers independently of visceral fat in
men. Obesity (Silver Spring) 2008;16(June (6)):1394–9.
[14] Ridker PM. C-reactive protein and the prediction of cardiovascular events
among those at intermediate risk:moving an inﬂammatory hypothesis toward
consensus. J Am Coll Cardiol 2007;49(21):2129–38.
[15] Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B. Combined
effects of hemoglobin A1c and C-reactive protein on the progression of subclini-
cal carotid atherosclerosis: the INVADE study. Stroke 2006;37(2):351–7.
[16] KarakasM, KoenigW. CRP in cardiovascular disease. Herz 2009;34(8):607–13.
[17] O’Leary DH, Polak JF. Intima–media thickness: a tool for atherosclerosis
imaging and event prediction. Am J Cardiol 2002;21(90 (10C)):18L–21L.
[18] O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK.
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study Collabora-
tive Research Group. N Engl J Med 1999;340(1):14–22.
[19] Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations
between carotid artery wall thickness and liver histology in subjects with
nonalcoholic fatty liver disease. Diabetes Care 2006;29(6):1325–30.
[20] Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S,
et al. Magnetic resonance spectroscopy to measure hepatic triglyceride con-
tent: prevalence of hepatic steatosis in the general population. Am J Physiol
Endocrinol Metab 2005;288(2):E462–8.
[21] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem 1972;18(6):499–502.
[22] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasismodel assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia
1985;28(7):412–9.
[23] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new worldwide deﬁni-
tion: a consensus statement from the International Diabetes Federation.
Diabetic Med 2006;23:469–80.
[24] Tushuizen ME, BunckMC, Pouwels PJ, Bontemps S, Mari A, Diamant M. Lack of
association of liver fat with model parameters of beta-cell function in men
with impaired glucose tolerance and type 2 diabetes. Eur J Endocrinol
2008;159:251–7.
[25] Provencher SW. Estimation of metabolite concentrations from localized in
vivo proton NMR spectra. Magn Reson Med 1993;30(6):672–9.
[26] Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J,
Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in
insulin suppression of glucose production and serum free fatty acids indepen-
dent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023–8.
[27] Toledo FG, Sniderman AD, Kelley DE. Inﬂuence of hepatic steatosis (fatty liver)
on severity and composition of dyslipidaemia in type 2 diabetes. Diabetes Care
2006;29:1845–50.
[28] Adiels M, Taskinen MR, Bore´n J. Fatty liver, insulin resistance, and dyslipi-
daemia. Curr Diab Rep 2008;8:60–4.
[29] Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the
pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med
2009;9(3):299–314.
[30] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy
subjects: associations with obesity, insulin resistance, and endothelial dys-
function: a potential role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol 1999;19(4):972–8.
[31] Festa A, D’Agostino Jr R, Howard G, Mykka¨nen L, Tracy RP, Haffner SM. Chronic
subclinical inﬂammation as part of the insulin resistance syndrome: the Insulin
Resistance Atherosclerosis Study (IRAS). Circulation 2000;102(July (1)):42–7.
[32] Kotronen A, Vehkavaara S, Seppa¨la¨-Lindroos A, Bergholm R, Yki-Ja¨rvinen H.
Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab
2007;293(6):E1709–15.
